SLN Stock: Price, Earnings History and SEC Filings
Silence Therapeutics plc (SLN) last traded at $19.75, down 0.25% on the latest session and up 80.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.26 against an analyst estimate of $-0.32, a beat of 18.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SLN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.26 | $-0.32 | +18.75% |
| Mar 2026 | May 7, 2026 | $-0.32 | $-0.33 | +3.03% |
| Dec 2025 | Mar 5, 2026 | $-0.25 | $-0.32 | +21.88% |
| Sep 2025 | Nov 6, 2025 | $-0.45 | $-0.40 | -12.50% |
SLN beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How SLN reacts to earnings
Across its last 7 earnings releases, SLN moved 7.5% on average the next session, in either direction. It rose after 3 of 7 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-10 | Before open | +29.12% |
| 2026-05-07 | Before open | -5.57% |
| 2026-03-05 | Before open | -4.84% |
| 2025-11-06 | Before open | +3.37% |
| 2025-08-07 | Before open | +1.13% |
| 2025-05-08 | Before open | -3.78% |
| 2025-02-27 | After close | -4.66% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
SLN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $559000 | -$89M | -$62M | -15851.9% | $-0.63 |
| 2024 | $43M | -$45M | -$68M | -104.7% | $-0.33 |
| 2023 | $32M | -$54M | -$50M | -171.4% | $-0.49 |
| 2022 | $22M | -$50M | -$57M | -232.4% | $-0.52 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SLN
- 8-K · Oct 19, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 12, 2026Material agreement, Other events, Financial statements and exhibits
- 424B5 · Aug 12, 2026
- 424B5 · Aug 10, 2026
- 8-K · Aug 10, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 10, 2026
- 8-K · Aug 10, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 23, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 16, 2026Shareholder vote
- 8-K · Jun 11, 2026Other events, Financial statements and exhibits
Insider filing activity
SLN insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
SLN news
- A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayOct 20, 2026 · finance.yahoo.com
- Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?Oct 20, 2026 · finance.yahoo.com
- Is Silence Therapeutics (NasdaqGM:SLN) Reasonable Near Its $20 Deal Price?Oct 20, 2026 · finance.yahoo.com
- Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%Oct 19, 2026 · finance.yahoo.com
- Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%Oct 19, 2026 · finance.yahoo.com
- Silence Therapeutics jumps 59% on Merck takeoverOct 19, 2026 · proactiveinvestors.com
- Silence Therapeutics stock soars 125% on Merck acquisitionOct 19, 2026 · finance.yahoo.com
- Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, GermanyOct 19, 2026 · finance.yahoo.com
About Silence Therapeutics plc
Silence Therapeutics plc (SLN) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in United Kingdom.